Original Article

Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Hope Northrup MD a,*, Darcy A. Krueger MD PhD b, on behalf of the International Tuberous Sclerosis Complex Consensus Group

a Division of Medical Genetics, Department of Pediatrics, University of Texas Medical School at Houston, Houston, Texas
b Division of Neurology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

ABSTRACT

BACKGROUND: Tuberous sclerosis complex is highly variable in clinical presentation and findings. Disease manifestations continue to develop over the lifetime of an affected individual. Accurate diagnosis is fundamental to implementation of appropriate medical surveillance and treatment. Although significant advances have been made in the past 15 years in the understanding and treatment of tuberous sclerosis complex, current clinical diagnostic criteria have not been critically evaluated or updated since the last clinical consensus conference in 1998. METHODS: The 2012 International Tuberous Sclerosis Complex Consensus Group, comprising 79 specialists from 14 countries, was organized into 12 subcommittees, each led by a clinician with advanced expertise in tuberous sclerosis complex and the relevant medical subspecialty. Each subcommittee focused on a specific disease area with important diagnostic implications and was charged with reviewing prevalence and specificity of disease-associated clinical findings and their impact on suspecting and confirming the diagnosis of tuberous sclerosis complex. RESULTS: Clinical features of tuberous sclerosis complex continue to be a principal means of diagnosis. Key changes compared with 1998 criteria are the new inclusion of genetic testing results and reducing diagnostic classes from three (possible, probable, and definite) to two (possible, definite). Additional minor changes to specific criterion were made for additional clarification and simplification. CONCLUSIONS: The 2012 International Tuberous Sclerosis Complex Diagnostic Criteria provide current, updated means using best available evidence to establish diagnosis of tuberous sclerosis complex in affected individuals.

Keywords: diagnostic criteria, clinical features, tuberous sclerosis

See related articles on pages 223 and 255.

Introduction

Tuberous sclerosis complex (TSC) was initially described approximately 150 years ago by von Recklinghausen in 1862.1 TSC is an extremely variable disease that can affect virtually any organ in the body. The most common findings are benign tumors in the skin, brain, kidneys, lung, and heart that lead to organ dysfunction as the normal parenchyma is replaced by a variety of cell types.2 Disease manifestations in different organ systems can vary widely between even closely related individuals and the protean nature of the condition can make clinical diagnosis challenging. TSC was underdiagnosed until the 1980s when individuals with less severe manifestations of the disease began to be recognized. Before the 1980s, incidence rates for TSC were quoted at between 1/100,000 and 1/200,000.3,4 Recent studies estimate a frequency of 1/6000 to 1/10,000 live births and a population prevalence of around 1 in 20,000.5,6 Although TSC was recognized to be a genetic disease more than 100 years ago,7 the underlying molecular etiology was not unraveled until the discovery of the two causative genes, TSC1 and TSC2.8,9

The second International Tuberous Sclerosis Complex Consensus Conference was held June 13–14, 2012, in Washington, DC. Seventy-nine experts (Appendix) from 14 countries assembled to review the evidence for diagnostic criteria and recommendations for future clinical research in TSC. The Conference was co-chaired by Drs. Hope Northrup and Darcy Krueger.

* Communications should be addressed to: Dr. Northrup; Division of Medical Genetics; Department of Pediatrics; The University of Texas Medical School at Houston; MSB 3.144B; Houston, TX 77030.
E-mail address: hope.northrup@uth.tmc.edu

Pediatr Neurol 2013; 49: 243-254
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.

See related articles on pages 223 and 255.

Introduction

Tuberous sclerosis complex (TSC) was initially described approximately 150 years ago by von Recklinghausen in 1862.1 TSC is an extremely variable disease that can affect virtually any organ in the body. The most common findings are benign tumors in the skin, brain, kidneys, lung, and heart that lead to organ dysfunction as the normal parenchyma is replaced by a variety of cell types.2 Disease manifestations in different organ systems can vary widely between even closely related individuals and the protean nature of the condition can make clinical diagnosis challenging. TSC was underdiagnosed until the 1980s when individuals with less severe manifestations of the disease began to be recognized. Before the 1980s, incidence rates for TSC were quoted at between 1/100,000 and 1/200,000.3,4 Recent studies estimate a frequency of 1/6000 to 1/10,000 live births and a population prevalence of around 1 in 20,000.5,6 Although TSC was recognized to be a genetic disease more than 100 years ago,7 the underlying molecular etiology was not unraveled until the discovery of the two causative genes, TSC1 and TSC2.8,9

The second International Tuberous Sclerosis Complex Consensus Conference was held June 13–14, 2012, in Washington, DC. Seventy-nine experts (Appendix) from 14 countries assembled to review the evidence for diagnostic criteria and recommendations for future clinical research in TSC. The Conference was co-chaired by Drs. Hope Northrup and Darcy Krueger.

* Communications should be addressed to: Dr. Northrup; Division of Medical Genetics; Department of Pediatrics; The University of Texas Medical School at Houston; MSB 3.144B; Houston, TX 77030.
E-mail address: hope.northrup@uth.tmc.edu

Pediatr Neurol 2013; 49: 243-254
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.

See related articles on pages 223 and 255.

Introduction

Tuberous sclerosis complex (TSC) was initially described approximately 150 years ago by von Recklinghausen in 1862.1 TSC is an extremely variable disease that can affect virtually any organ in the body. The most common findings are benign tumors in the skin, brain, kidneys, lung, and heart that lead to organ dysfunction as the normal parenchyma is replaced by a variety of cell types.2 Disease manifestations in different organ systems can vary widely between even closely related individuals and the protean nature of the condition can make clinical diagnosis challenging. TSC was underdiagnosed until the 1980s when individuals with less severe manifestations of the disease began to be recognized. Before the 1980s, incidence rates for TSC were quoted at between 1/100,000 and 1/200,000.3,4 Recent studies estimate a frequency of 1/6000 to 1/10,000 live births and a population prevalence of around 1 in 20,000.5,6 Although TSC was recognized to be a genetic disease more than 100 years ago,7 the underlying molecular etiology was not unraveled until the discovery of the two causative genes, TSC1 and TSC2.8,9

The second International Tuberous Sclerosis Complex Consensus Conference was held June 13–14, 2012, in Washington, DC. Seventy-nine experts (Appendix) from 14 countries assembled to review the evidence for diagnostic criteria and recommendations for future clinical research in TSC. The Conference was co-chaired by Drs. Hope Northrup and Darcy Krueger.

* Communications should be addressed to: Dr. Northrup; Division of Medical Genetics; Department of Pediatrics; The University of Texas Medical School at Houston; MSB 3.144B; Houston, TX 77030.
E-mail address: hope.northrup@uth.tmc.edu

Pediatr Neurol 2013; 49: 243-254
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.
countries convened to finalize diagnostic, surveillance, and management recommendations for patients with TSC. A summary report of the current, updated surveillance and management recommendations for patients with TSC is provided separately. One of the major goals of the conference was to revisit the clinical diagnostic criteria published subsequent to the first International TSC Consensus Conference in 1998. Since 1998, one additional manuscript regarding the diagnostic criteria was published that was designed to provide more guidance to practitioners by including pictures of the major and minor findings. At the 2012 meeting, the most significant change recommended to the diagnostic criteria was the incorporation of genetic testing. Although the TSC1 and TSC2 genes were discovered before the 1998 conference, molecular testing was not widely available at that time. Molecular testing of the TSC1 and TSC2 genes yields a positive mutation result for 75-90% of TSC-affected individuals categorized as “definite” by the 1998 Consensus Conference Clinical Diagnostic Criteria. The use of molecular testing in medicine has expanded greatly since the 1990s, becoming widely accepted as invaluable in the diagnosis of diseases with a genetic basis. Utilization of genetic testing for TSC was addressed along with refinement of clinical criteria.

### Genetic diagnostic criteria

Comprehensive and reliable screens for TSC1 and TSC2 mutations are well-established, and many pathogenic mutations have been identified (www.lovd.nl/TSC1, www.lovd/TSC2). The recommendation of the Genetics Panel was to make identification of a pathogenic mutation in TSC1 or TSC2 an independent diagnostic criterion, sufficient for the diagnosis or prediction of TSC regardless of the clinical findings (Table part A). This will facilitate the diagnosis of TSC in some, particularly young individuals, allowing earlier implementation of surveillance and treatment with potential for better clinical outcomes. A “pathogenic” mutation was defined as a mutation that clearly prevents protein synthesis and/or inactivates the function of the TSC1 or TSC2 proteins (e.g., nonsense mutation or frameshift mutations, large genomic deletions) or is a missense mutation whose effect on protein function has been established by functional assessment. TSC1 and TSC2 genetic variants whose functional effect is less certain are not definitely pathogenic and would not be considered a major diagnostic criterion. A significant fraction (10-25%) of TSC patients have no mutation identified by conventional genetic testing. Nonetheless, if the mutation in an affected relative is known, testing for that mutation has very high predictive value for family members. Assembled experts at the Consensus Conference agreed with the recommendation that identification of a pathogenic mutation in TSC1 or TSC2 is an independent diagnostic criterion.

### Clinical diagnostic criteria

In addition to diagnosis by genetic analysis, the clinical diagnostic criteria used to establish the diagnosis of TSC were also reviewed at the conference. Special attention was

| TABLE. Updated diagnostic criteria for tuberous sclerosis complex 2012 |
|--------------------|-------------------|-----------------|
| A. Genetic diagnostic criteria | | |
| The identification of either a TSC1 or TSC2 pathogenic mutation in DNA from normal tissue is sufficient to make a definite diagnosis of tuberous sclerosis complex (TSC). A pathogenic mutation is defined as a mutation that clearly inactivates the function of the TSC1 or TSC2 proteins (e.g., out-of-frame indel or nonsense mutation), prevents protein synthesis (e.g., large genomic deletion), or is a missense mutation whose effect on protein function has been established by functional assessment (www.lovd.nl/TSC1, www.lovd/TSC2, and Hoogeveen-Westerveld et al., 2012 and 2013). Other TSC1 or TSC2 variants whose effect on function is less certain do not meet these criteria, and are not sufficient to make a definite diagnosis of TSC. Note that 10% to 25% of TSC patients have no mutation identified by conventional genetic testing, and a normal result does not exclude TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC. |
| B. Clinical diagnostic criteria | | |
| Major features | | |
| 1. Hypomelanotic macules (≥3, at least 5-mm diameter) | | |
| 2. Angiofiromas (≥3) or fibrous cephalic plaque | | |
| 3. Ungual fibromas (≥2) | | |
| 4. Shagreen patch | | |
| 5. Multiple retinal hamartomas | | |
| 6. Cortical dysplasias | | |
| 7. Subependymal nodules | | |
| 8. Subependymal giant cell astrocytoma | | |
| 9. Cardiac rhabdomyoma | | |
| 10. Lymphangioleiomyomatosis (LAM) | | |
| 11. Angiomyolipomas (≥2) | | |
| Minor features | | |
| 1. “Confetti” skin lesions | | |
| 2. Dental enamel pits (≥3) | | |
| 3. Intraoral fibromas (≥2) | | |
| 4. Retinal achromatic patch | | |
| 5. Multiple renal cysts | | |
| 6. Nonrenal hamartomas | | |
| Definite diagnosis: Two major features or one major feature with ≥2 minor features | | |
| Possible diagnosis: Either one major feature or ≥2 minor features | | |
| Includes tubers and cerebral white matter radial migration lines. |
| * A combination of the two major clinical features (LAM and angiomyolipomas) without other features does not meet criteria for a definite diagnosis. |
Dermatologic and dental features

The dermatology and dental panel recommended retaining the existing mucocutaneous criteria and suggested minor changes regarding their number, size, or nomenclature. The major features (with changes italicized) include: (1) hypomelanotic macules (≥3, at least 5-mm diameter), (2) angiofibromas (≥3) or fibrous cephalic plaque, (3) ungual fibromas (≥2), and (4) shagreen patch. The revised minor features include: (1) “confetti” skin lesions, (2) dental enamel pits (≥3), and (3) intraoral fibromas (≥2). Nearly 100% of individuals affected with TSC have skin or dental findings of the disease that are easily detectable on physical examination. It is therefore important that these features be highlighted to aid in bringing TSC patients to medical attention.

Hypomelanotic macules

Hypomelanotic macules are a significant feature because they are observed in about 90% of individuals with TSC, they typically appear at birth or infancy, and they may be a presenting sign of TSC (Fig 1).15–21 At the 1998 Consensus, it was stipulated that an individual must have three or more hypopigmented macules, because one or two lesions are relatively common in the general population.22,23 In the updated criteria, it was recommended that hypomelanotic macules meet a size requirement of at least 5-mm diameter to distinguish hypomelanotic macules from smaller and more numerous “confetti” lesions. In addition, it was suggested that poliosis, circumscribed areas of hypomelanosis of hair, be included in the count of hypomelanotic macules.

Angiofibromas or fibrous cephalic plaque

Facial angiofibromas occur in about 75% of TSC patients (Fig 2),15,16,18,21 with onset typically between ages 2 and 5 years.24 Although most TSC patients have several facial angiofibromas, milder cases of TSC with limited facial angiofibromas have been described. However, because one or two isolated sporadic lesions may be observed in the general population,25 the presence of at least three facial angiofibroma lesions is now recommended to meet this major criteria for TSC. Multiple facial angiofibromas have also been observed in Birt-Hogg-Dubé (BHD) syndrome, and multiple endocrine neoplasia type 1 (MEN1).26,27 In these conditions, the age of onset of angiofibromas is later than in TSC. Therefore, multiple facial angiofibromas remain a major feature for diagnosis when their onset occurs in childhood. In the unusual circumstance when angiofibromas have their onset in adulthood, they should be considered as a minor feature and the differential diagnosis expanded to include BHD and MEN1. When angiofibromas are few or later in onset, a skin biopsy may be required to confirm the clinical diagnosis.

The forehead plaque is observed in about 25% of TSC patients and this feature was paired with angiofibromas for the diagnostic criteria in 1998 (Fig 3A). The panel recommended changing the terminology from forehead plaque to fibrous cephalic plaque. This term was created to increase awareness that these fibrous plaques, although often located unilaterally on the forehead, may occur on other parts of the face or scalp (Fig 3B). Fibrous cephalic plaques, which are histologically similar to angiofibromas, may be the most specific skin finding for TSC.

Ungual fibromas

Ungual fibromas were retained as a major feature (Fig 4). The previous designation as “nontraumatic” was eliminated because recall of trauma may be unreliable and trauma may play a role in the formation of TSC ungual fibromas.28 This designation was replaced with the requirement that they be
multiple (≥2) because ungual fibromas that occur in the general population in response to trauma are usually solitary.29 The redundant phrase “ungual and periungual fibromas” was replaced with “ungual fibromas” used to encompass both periungual and subungual fibromas. Ungual fibromas are less common than some of the other TSC skin findings, with a frequency of about 20% overall but as high as 80% in older adults.15,16,28 The greater frequency in adults is due to later onset, typically in the second decade or later.18,21 Therefore, their utility in diagnosis is usually limited to adolescents and adults.24

**Shagreen patch**

The presence of a shagreen patch was retained as a major feature, but the criterion was updated by deletion of “connective tissue nevus” because this term encompasses a variety of skin lesions with excessive dermal connective tissue that are not necessarily associated with TSC. Shagreen patches commonly take the form of large plaques on the lower back that have a bumpy or orange-peel surface, and this clinical appearance is nearly always specific for TSC (Fig 5). Smaller collagenomas on the trunk exhibit the same histologic changes as shagreen patches but are less specific for TSC because they may also occur as an isolated finding or in other genetic syndromes including MEN1,26 BHD,30 and Cowden syndrome.31 Shagreen patches are observed in about 50% of individuals with TSC and typically have their onset in the first decade of life.15,16,18,21

**“Confetti” skin lesions**

Confetti skin lesions are numerous 1- to 3-mm hypopigmented macules scattered over regions of the body such as the arms and legs.31 Their frequency varies widely in different studies, from 3% in children to about 58% overall.15,24 Despite their relatively low frequency, confetti lesions may still be useful for diagnosis and they were retained as a minor feature. Their utility in adults is limited by the fact that many adults in the general population develop similar-appearing lesions as a consequence of chronic sun exposure. In such cases, the diagnosis of confetti lesions may be supported by a history of onset in

---

**FIGURE 3.**
(A) Fibrous plaque on face. (B) Fibrous plaque on scalp.

**FIGURE 4.**
Ungual fibromas.

**FIGURE 5.**
Shagreen patch on dorsolumbar area of back.
the first decade of life or by asymmetric involvement of one body region over another.

*Dental enamel pits*

Dental enamel pits, previously included as a minor feature listed as “multiple, randomly distributed pits in dental enamel” were again included as a minor feature (Fig 6). The designation was simplified to dental enamel pits (≥3) for the entire dentition. Dental pits are much more common in TSC patients than the general population, with Mlynarczyk reporting 100% of adult TSC patients (n = 50) as having pitting compared with 7% of 250 adult control subjects.32 Because they are relatively common in the population, they are listed as a minor feature.

*Intraoral fibromas*

Gingival fibromas have long been associated with TSC and were listed as a minor feature in the 1998 consensus document (Fig 7). They occur in about 20-50% of individuals with TSC, with greater frequency in adults than children.15,21,33,34 Fibromas in TSC may also be observed on the buccal or labial mucosa and even the tongue,34 so this criterion was modified to include fibromas at other intraoral sites. A stipulation was added for the presence of two or more intraoral fibromas because solitary oral fibromas may occur in the general population, particularly on the tongue or buccal mucosa along the bite line from repeated trauma.35,36

*Bone cysts*

Bone cysts were included in the 1998 criteria as a minor feature of TSC. Because of the lack of specificity for TSC and because the feature is rarely identified in the absence of additional TSC clinical features, a decision was made to delete “bone cysts” from the clinical diagnostic criteria.

*Ophthalmologic features*

*Multiple retinal hamartomas*

The finding of more than one retinal hamartoma was determined to be significant and specific enough to retain as a major feature (Fig 8). These lesions have similar histologic features to the tubers located in the brains of TSC patients. They are observed in 30-50% of TSC patients and it is not unusual to have multiple lesions in the same patient.37,38 The prevalence of retinal hamartomas in non-TSC populations is not known, but rare case reports have been made and a recent series of 3573 healthy term newborns identified only two cases of astrocytic hamartomas in that population.39 Fortunately, these lesions in TSC usually do not cause problems with vision and are a good marker for the disease, particularly in young children who might not yet have many other features.

*Retinal achromatic patch*

The presence of a retinal achromatic patch was determined at the 1998 conference to constitute a minor feature (Fig 9). The assembled experts at the 2012 conference concurred with the previous recommendation. Retinal achromatic patches are basically areas of hypopigmentation on the retina. These patches have been noted to occur in 39% of TSC patients.
patients.38,40 Incidence in the general population is estimated at 1 in 20,000.41

Central nervous system features

Because medical problems relating to the brain result in the greatest morbidity and mortality in TSC, three panels at the 2012 Consensus Conference devoted their efforts to central nervous system–related findings of TSC. The panels were: (3) brain structure, tubers, and tumors; (4) epilepsy; and (5) TSC-associated neuropsychiatric disorders. The three panels were in agreement that there should be three neurological findings categorized as major features and that the minor feature of cerebral white matter radial migration lines should be subsumed into one of the major features as reviewed in the following sections. Thus, findings relating to the central nervous were streamlined.

Cortical dysplasias

Cortical dysplasias are congenital abnormalities caused, at least in part, when a group of neurons fail to migrate to the proper area of the brain during development. The cortical tubers observed in ~90% of TSC patients and the pathologic finding for which the disorder is named, are a type of focal cortical dysplasia. Cerebral white matter radial migration lines arise from a similar pathologic process as cortical tubers and other forms of cortical dysplasia and in TSC it is not unusual to find tubers and white matter migrational abnormalities together (Fig 10A). Both types of cortical dysplasia in TSC are commonly associated with intractable epilepsy and learning difficulties in TSC. The pathologic and clinical overlap between “cortical tuber” as a major feature and “cerebral white matter radial migration lines” as a minor feature in the 1998 diagnostic criteria were felt to no longer represent separate processes and are replaced with a single major feature in the new classification “cortical dysplasia.” However, it is appreciated that a single area of focal cortical dysplasia or even two can be observed in an individual who does not have TSC; thus, in the new diagnostic criteria, multiple areas of focal cortical dysplasia count only as one major feature and additional clinical features are necessary to establish a definite diagnosis of TSC.

Subependymal nodules and subependymal giant cell astrocytomas

Subependymal nodules (SEN) and subependymal giant cell astrocytoma (SEGA) will continue to represent two separate major features (Fig 10B). Both of these lesions were also included in the 1998 Consensus Conference Criteria as major features. Histologically, the two lesions are similar and both are relatively specific to TSC although not exclusive to the disorder. Subependymal nodules are benign growths that develop along the wall of the ependymal lining of the lateral and third ventricles. They are observed in 80% of TSC patients and often prenatally detected or at birth.42 SEGAs

FIGURE 9.
Retinal achromatic patch indicated by arrow.

FIGURE 10.
(A) Axial magnetic resonance imaging (MRI) (T2 fluid-attenuated inversion recovery) of the brain, demonstrating cortical dysplasia (tubers and radial migration lines indicated by white and black arrows, respectively). (B) Axial MRI (T1 + contrast) of the brain, demonstrating subependymal nodules (left, two white arrows) and subependymal giant cell astrocytoma (right, black arrow). This patient also has undergone previous partial frontal lobectomy for epilepsy.
have an incidence of 5-15% in TSC and may also be detected prenatally or at birth, although they are much more likely to arise during childhood or adolescence and it would be unusual for one to occur after the age of 20 years if not already previously present. It is widely accepted that SEGAs typically arise from SEN, especially near the foramen of Monro. Although benign and typically slow-growing, they can cause serious neurologic compromise including obstructive hydrocephalus. Both SENs and SEGAs may progressively calcify over time.

Cardiovascular features

The cardiology panel recommended retaining “cardiac rhabdomyoma” as a major feature and determined that there is no need to specify one versus more than one.

Cardiac rhabdomyoma

Cardiac rhabdomyomas are benign tumors of the heart that are rarely observed in non-TSC-affected individuals. These lesions usually do not cause serious medical problems, but they are highly specific to TSC and often the first noted manifestation of disease, and therefore remain a major feature. Tumors are most frequently located in the ventricles, where they can compromise ventricular function and on occasion interfere with valve function or result in outflow obstruction. These tumors are frequently observed in TSC-affected individuals during fetal life but after birth, they often regress and in some individuals may no longer be detectable by echocardiographic examination. They are associated with cardiac arrhythmias including atrial and ventricular arrhythmia and the Wolff-Parkinson-White syndrome.

The prenatal presence of a cardiac rhabdomyoma is associated with a 75-80% risk of TSC, with multiple rhabdomyomas conveying an even higher risk. Further, in the era preceding genetic testing, there was a <0.1% occurrence of cardiac rhabdomyoma in individuals not affected with TSC. Because they are frequently observed in fetal life, unlike other findings in TSC, they are important in bringing the patient to medical attention early in life. At that point, new interventions may be more likely to improve prognosis.

Pulmonary features

The pulmonology panel recommended retaining the finding of lymphangioleiomyomatosis (LAM) as a major feature of the clinical criteria to diagnose TSC. The other experts agreed with this recommendation.

Lymphangioleiomyomatosis

Histologically, LAM is associated with interstitial expansion of the lung with benign-appearing smooth muscle cells that infiltrate all lung structures. Patients typically present with progressive dyspnea on exertion and recurrent pneumothoraces in the third to fourth decade of life. Cystic pulmonary parenchymal changes consistent with LAM are observed in 30-40% of female TSC patients, but recent studies suggest that lung involvement may increase with age such that up to 80% of TSC females are affected by age 40. Cystic changes consistent with LAM are also observed in about 10-12% of males with TSC, but symptomatic LAM in males is very rare. It is important to note that lung is rarely biopsied in TSC patients with pulmonary parenchymal changes, so it is possible that processes other than LAM may result in cystic lung disease in TSC patients. LAM is also diagnosed in individuals who do not have TSC, and is referred to as sporadic LAM (S-LAM). In these patients, LAM is thought to occur through two somatic mutations in the TSC2 gene, rather than through a germ line mutation and a “second-hit” somatic mutation that is typical for TSC. That about one third of S-LAM patients have renal angiomyolipomas, another major feature in the diagnostic criteria for TSC, led to the conclusion by the 1998 consensus group that when both angiomyolipoma and LAM were present, other TSC features must be present for the diagnosis of TSC (status per current Consensus Conference discussed in next section).
members of the pulmonology panel agreed with the principle that TSC diagnostic criteria must clearly differentiate S-LAM from TSC-LAM, and suggested the following modified language: "When angiomyolipomas and LAM are both present in a patient with suspected TSC, together they constitute only one major criterion."

The diagnosis of LAM as defined by the pulmonology panel is: (1) pathologic examination consistent with LAM, (2) characteristic as defined by the European Respiratory Society (ERS) criteria high-resolution chest computed tomography (HRCT) with profusion of cysts (>4) and no confounding comorbidity conditions or exposures in a patient with at least one other major criteria for TSC (other than angiomyolipoma), or two other minor criteria, OR (3) characteristic or compatible (ERS criteria) HRCT in the setting of no confounding comorbidity conditions or exposures, plus one of the following: abdominal or thoracic lymphangioleiomyomas, chylous pleural effusion, or chylous ascites.

Other manifestations of tuberous sclerosis in the lung include multifocal micronodular pneumocyte hyperplasia (MMPH) and clear cell tumor of the lung. In MMPH, multiple pulmonary nodules composed of benign alveolar type II cells are found scattered throughout the lung. These lesions stain with cytokeratin and surfactant proteins A and B, but not with HMB-45, alpha smooth muscle actin, or hormonal receptors. MMPH does not have known prognostic or physiologic consequences, although there have been at least two reports of respiratory failure associated with MMPH. The precise prevalence of MMPH in patients with TSC is not known, but may be as high as 40-58%. There is no gender restriction and MMPH may occur in the presence or absence of LAM in patients with TSC. MMPH can be confused with atypical adenomatous hyperplasia, which is premalignant lesion that is not clearly associated with TSC. Clear cell tumor of the lung (CCSTL) is a rare and typically benign mesenchymal tumor composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. Together LAM, angiomyolipoma, and CCSTL constitute the major members of the PEComa family of lung tumors. The members of the pulmonary subcommittee did not feel that the specificity of MMPH and CCSTL for TSC have been established with sufficient clarity to suggest their inclusion as diagnostic criteria.

Renal features

The nephrology panel attending the Consensus Conference agreed with deleting the designation of "renal" in the major feature "renal angiomyolipomas" to now use "angiomyolipomas ≥2" in the clinical diagnostic criteria. Angiomyolipomas have been identified in TSC patients in organs other than the kidney including the liver. As a result, "angiomyolipomas (≥2)" was added to the major features. The nephrology panel recommended not using the abbreviation "AMLS" for angiomyolipomas. Although this abbreviation has been commonly used among individuals familiar with TSC, in most medical contexts it is more familiarly associated with acute myelocytic leukemia and thus introduces confusion across specialties. The nephrology panel also recommended retaining "multiple renal cysts" as a minor feature. This recommendation was accepted by the other panelists. Additionally, it was agreed that an individual who has LAM and renal angiomyolipomas but no other features of TSC does not meet criteria for a definite diagnosis because of the previously reviewed information regarding S-LAM.

Renal manifestations in TSC are an important source of morbidity and mortality. In the only publication assessing mortality associated with TSC, renal problems in TSC were the second leading cause of premature death after severe intellectual disability. With advances in medical care, death in TSC from renal disease is much less likely; however, it continues to represent a significant medical burden to TSC patients.

Angiomyolipomas

Angiomyolipomas are benign tumors composed of vascular, smooth muscle, and adipose tissue (Fig 13). These benign tumors are observed most commonly in TSC patients in the kidney but can occur in other organs. To be inclusive of angiomyolipomas in other organs, it was decided to delete "renal" and simply use the term "angiomyolipomas (N ≥ 2)" as a major recognized feature. Angiomyolipomas are a feature relatively specific to TSC. Fat-containing angiomyolipomas were observed in 80% of TSC patients, and fat-poor lesions are also common in patients with TSC, but occur in less than 0.1% of the general population. Angiomyolipomas in the kidney can cause serious issues with bleeding because of its vascular nature and can lead to need for dialysis and even renal transplantation.

Multiple renal cysts

Multiple renal cysts are not commonly observed in the general population, but can be seen in TSC patients who
have a TSC1 or TSC2 mutation or as part of a contiguous gene deletion syndrome involving the TSC2 and PKD1 genes.\(^6^2\) The TSC2 and PKD1 genes are immediately adjacent and transcribed in opposite directions on chromosome 16p13.3. Deletions involving both genes have been described in a small subset of TSC patients who have the TSC phenotype as well as an aggressive PKD phenotype.\(^6^6\) Presence of multiple simple renal cysts in older individuals in the general population is well-described, thus the decision was made to specify multiple renal cysts and relegate this feature to the minor status. In cross-sectional studies the number of cysts in healthy people vary with age and standards have been derived to help diagnose specific cystic disease states.

**Endocrine features**

Limited findings of TSC have been reported in the endocrine system. Various kinds of hamartoma do occur in the endocrine system.\(^6^7\) According to early reports, adrenal angiomyolipoma can be present in a quarter of TSC patients, but rarely, if ever, causes hemorrhage.\(^6^8\) Thyroid papillary adenoma have been reported in TSC patients,\(^6^9\)\(^7^0\) but did not cause thyroid dysfunction. There are rare case reports of other angiomyolipoma or fibroadenoma in the pituitary gland, pancreas, or gonads.\(^6^7\) These tumors are considered as representing minor features under the designation “nonrenal hamartomas.” The recommendation was made by the endocrinology panel to retain nonrenal hamartomas as a minor feature to include these findings in the endocrine system of TSC-affected individuals. It was speculated that neuroendocrine tumors might be slightly more prevalent in TSC patients.\(^6^7\)\(^7^3\) However, neuroendocrine tumors are not hamartomas and are not considered part of the diagnostic criteria.

**Gastrointestinal features**

Similarly, gastrointestinal manifestations in TSC patients are fairly rare. Liver angiomyolipomas are reported in 10–25% of TSC patients,\(^7^4\) and these lesions are included in the major features group under the heading “Angiomyolipomas” (discussed previously). Hamartomatous rectal polyps were included as a minor feature in the 1998 Diagnostic Criteria. It was decided because of the lack of specificity for TSC and because they are another type of “nonrenal hamartoma” that the specific designation of “hamartomatous rectal polyps” would be deleted from the minor criteria.

**Acknowledgments**

The 2012 International TSC Clinical Consensus Conference was sponsored and organized by the Tuberous Sclerosis Alliance. The conference was supported by generous sponsors who donated funds to the Tuberous Sclerosis Alliance without playing a role in the planning or having a presence at the conference or any influence on the resulting recommendations: the Rothberg Institute for Childhood Diseases, Novartis Pharmaceuticals, Sandra and Brian O’Brien, and Questcor Pharmaceuticals.

**References**


Appendix. Members of the 2012 International TSC Consensus Group

<table>
<thead>
<tr>
<th>Conference co-chairs:</th>
<th>Hope Northrup MD (Houston, Texas)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Darcy A. Krueger MD, PhD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td>TS Alliance representatives:</td>
<td>Steven Roberds PhD (Silver Spring, Maryland)</td>
</tr>
<tr>
<td></td>
<td>Julian Sampson DM, FRCP, FMedSci (Cardiff, Wales, UK)</td>
</tr>
<tr>
<td></td>
<td>Bruce Korf MD, PhD (Birmingham, Alabama)</td>
</tr>
<tr>
<td></td>
<td>Katie Smith (Silver Spring, Maryland)</td>
</tr>
<tr>
<td></td>
<td>Darcy A. Krueger MD, PhD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td></td>
<td>Mark Nellist PhD (Rotterdam, The Netherlands)</td>
</tr>
<tr>
<td></td>
<td>Sue Povey MD (London, England, UK)</td>
</tr>
<tr>
<td>TSC-associated neuropsychiatric disorders chair:</td>
<td>Petrus de Vries MBChB, MRCPsych, PhD (Cape Town, South Africa)</td>
</tr>
<tr>
<td>TSC-associated neuropsychiatric disorders committee:</td>
<td>Anna Byars PhD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td></td>
<td>Kevin Ess MD, PhD (Nashville, Tennessee)</td>
</tr>
<tr>
<td></td>
<td>Dena Hook (Silver Spring, Maryland)</td>
</tr>
<tr>
<td></td>
<td>Anna Jansen MD, PhD (Brussels, Belgium)</td>
</tr>
<tr>
<td></td>
<td>Bryan King MD (Seattle, Washington)</td>
</tr>
<tr>
<td></td>
<td>Mustafa Sahin MD, PhD (Boston, Massachusetts)</td>
</tr>
<tr>
<td></td>
<td>Vicky Whittemore PhD (Bethesda, Maryland)</td>
</tr>
<tr>
<td>Epilepsy chair:</td>
<td>Elizabeth Thiele MD, PhD (Boston, Massachusetts)</td>
</tr>
<tr>
<td>Epilepsy committee:</td>
<td>E. Martina Bebin MD, MPA (Birmingham, Alabama)</td>
</tr>
<tr>
<td></td>
<td>Harry T. Chugani MD (Detroit, Michigan)</td>
</tr>
<tr>
<td></td>
<td>Peter Crino MD, PhD (Philadelphia, Pennsylvania)</td>
</tr>
<tr>
<td></td>
<td>Paolo Curatolo MD (Rome, Italy)</td>
</tr>
<tr>
<td></td>
<td>Greg Holmes MD (Lebanon, New Hampshire)</td>
</tr>
<tr>
<td></td>
<td>Rima Nabbout MD, PhD (Paris, France)</td>
</tr>
<tr>
<td></td>
<td>Finbar O'Callaghan MA, MB, MSc, PhD (Bristol, England, UK)</td>
</tr>
<tr>
<td></td>
<td>James Whole MD (Memphis, Tennessee)</td>
</tr>
<tr>
<td></td>
<td>Joyce Wu MD (Los Angeles, California)</td>
</tr>
<tr>
<td>Dermatology and dentistry chair:</td>
<td>Thomas N. Darling MD, PhD (Bethesda, Maryland)</td>
</tr>
<tr>
<td>Dermatology and dentistry committee:</td>
<td>Elizabeth Gosnell DMD (Columbus, Ohio)</td>
</tr>
<tr>
<td></td>
<td>Adelaide Hebert MD (Houston, Texas)</td>
</tr>
<tr>
<td></td>
<td>Greg Mlynarczyk DDS (Santa Rosa, California)</td>
</tr>
<tr>
<td></td>
<td>Keyomaurs Soltani, MD (Chicago, Illinois)</td>
</tr>
<tr>
<td></td>
<td>Joyce Teng MD, PhD (Palo Alto, California)</td>
</tr>
<tr>
<td></td>
<td>Mari Wataya-Kaneda MD, PhD (Osaka, Japan)</td>
</tr>
<tr>
<td></td>
<td>Patricia M. Witman MD (Columbus, Ohio)</td>
</tr>
<tr>
<td>Nephrology co-chair:</td>
<td>Chris Kingswood MSC, FRCP (Brighton, England, UK)</td>
</tr>
<tr>
<td>Nephrology co-chair:</td>
<td>John Bisler MD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td>Nephrology committee:</td>
<td>Klemens Budde MD (Berlin, Germany)</td>
</tr>
<tr>
<td></td>
<td>John Hultberg MD (Edina, Minnesota)</td>
</tr>
<tr>
<td></td>
<td>Lisa Guay-Woodford MD (Washington DC)</td>
</tr>
<tr>
<td></td>
<td>Julian Sampson DM, FRCP, FMedSci (Cardiff, Wales, UK)</td>
</tr>
<tr>
<td></td>
<td>Matthias Sauter MD (Munich, Germany)</td>
</tr>
<tr>
<td></td>
<td>Bernard Zonneberg MD, PhD (Utrecht, The Netherlands)</td>
</tr>
<tr>
<td>Brain structure, tubers and tumors chair:</td>
<td>Sergiusz Jóźwiak MD, PhD (Warsaw, Poland)</td>
</tr>
<tr>
<td>Brain structure, tubers and tumors committee:</td>
<td>Ute Bartels MD, MSc (Toronto, Ontario, Canada)</td>
</tr>
<tr>
<td></td>
<td>Moncef Berhouma MD (Lyon, France)</td>
</tr>
<tr>
<td></td>
<td>David Neal Franz MD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td></td>
<td>Mary Kay Koenig MD (Houston, Texas)</td>
</tr>
<tr>
<td></td>
<td>Darcy A. Krueger MD, PhD (Cincinnati, Ohio)</td>
</tr>
<tr>
<td></td>
<td>E. Steve Roach MD (Columbus, Ohio)</td>
</tr>
<tr>
<td></td>
<td>Jonathan Roth MD (Tel Aviv, Israel)</td>
</tr>
<tr>
<td></td>
<td>Henry Wang MD, PhD (Rockeplace, New York)</td>
</tr>
<tr>
<td></td>
<td>Howard Weiner MD (New York, New York)</td>
</tr>
<tr>
<td>Pulmonology chair:</td>
<td>Francis X. McCormack MD (Cincinnati, Ohio)</td>
</tr>
</tbody>
</table>
Pulmonology committee:  
Khalid Almoosa MD (Houston, Texas)  
Alan Brody MD (Cincinnati, Ohio)  
Charles Burger MD (Jacksonville, Florida)  
Vincent Cottin MD (Lyon, France)  
Geraldine Finlay MD (Boston, Massachusetts)  
Jennifer Glass MS (Cincinnati, Ohio)  
Elizabeth Petri Henske MD (Boston, Massachusetts)  
Simon Johnson MD (Nottingham, England, UK)  
Robert Kotloff MD (Philadelphia, Pennsylvania)  
David Lynch MD (Denver, Colorado)  
Joel Moss MD, PhD (Bethesda, Maryland)  
Karen Smith MLS (Bethesda, Maryland)  
Jay Rhu MD (Rochester, Minnesota)  
Angelo Taveira Da Silva MD, PhD (Bethesda, Maryland)  
Lisa R. Young MD (Nashville, Tennessee)

Cardiology chair:  
Timothy Knilans MD (Cincinnati, Ohio)

Cardiology committee:  
Robert Hinton MD (Cincinnati, Ohio)  
Ashwin Prakash MD (Boston, Massachusetts)  
Robb Romp MD (Birmingham, Alabama)  

Ophthalmology chair:  
Arun D. Singh MD (Cleveland, Ohio)

Gastroenterology chair:  
Ashish DebRoy MD (Houston, Texas, USA)

Endocrinology chair:  
Pei-Lung Chen MD, PhD (Taipei, Taiwan)

Care Integration chair:  
Steven Sparagana MD (Dallas, Texas)

Care integration committee:  
Michael D. Frost MD (St. Paul, Minnesota)